What is immunotherapy and how does it work against cancer
Ask Navis about your situation
This answer is general. Get one about your specific case — no signup, answered right here.
For informational purposes only
This answer was generated by AI grounded in NCCN guidelines and published medical literature. It is not medical advice. Always consult your oncologist or care team before making treatment decisions.
Understanding Immunotherapy: How Your Immune System Fights Cancer
Immunotherapy is a type of cancer treatment that works by helping your body's own immune system recognize and attack cancer cells. Rather than directly killing cancer cells like chemotherapy does, immunotherapy essentially "trains" or "unleashes" your immune system to do the job.
How Your Immune System Normally Works
Your body has a natural defense system (immune system) with special cells that patrol for threats—like viruses, bacteria, and abnormal cells. Normally, these immune cells should recognize cancer cells as dangerous and destroy them. But cancer is clever: it develops ways to hide from or trick your immune system into ignoring it.
How Immunotherapy Changes the Game
Immunotherapy works by removing the "disguise" cancer uses. Here are the main approaches:
Checkpoint Inhibitors (most common type)
- Cancer cells have "off switches" they use to disable immune cells nearby
- Checkpoint inhibitor drugs block these off switches
- This allows your immune cells to see and attack the cancer
- Examples include drugs targeting PD-1, PD-L1, and CTLA-4 pathways
CAR-T Cell Therapy
- Doctors remove some of your immune cells (T cells)
- They genetically modify them in the lab to better recognize cancer
- These "upgraded" cells are grown in large numbers and put back in your body
- Your enhanced immune cells then hunt down cancer cells
Other Approaches
- Cancer vaccines that teach your immune system to recognize specific cancer cells
- Monoclonal antibodies that mark cancer cells for destruction
- Therapies that boost overall immune function
Why Immunotherapy Matters
According to NCCN (National Comprehensive Cancer Network) Guidelines and ASCO (American Society of Clinical Oncology) recommendations, immunotherapy has become a cornerstone treatment for many cancer types—including melanoma, lung cancer, kidney cancer, and certain blood cancers. It's often used alone or combined with chemotherapy or targeted therapy.
Important Context
- Response varies: Some patients have dramatic responses; others see modest benefit
- Side effects differ: Rather than the typical chemo side effects, immunotherapy can cause immune-related side effects (your activated immune system may attack healthy tissue)
- Time to work: Immunotherapy often takes longer to show results than chemotherapy—sometimes weeks or months
- Biomarkers matter: Tests like PD-L1 expression and tumor mutational burden (TMB) help doctors predict who's most likely to benefit
Questions to Ask Your Oncologist
If immunotherapy is being considered for your situation:
- Is immunotherapy recommended for my specific cancer type and stage?
- What biomarkers or tests predict how I might respond?
- Will I receive immunotherapy alone or combined with other treatments?
- What immune-related side effects should I watch for?
- How will we measure whether the treatment is working?
This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.
Ask Navis about your case
That answer is general. Ask about your specific situation — no signup, answered right here.
Facing this with someone you love?
Keep the whole picture in one private place: records, a plain-language summary of where things stand, questions, and the people helping. Navis keeps it up to date so no one has to re-explain the story. Free, and only the people you invite can ever see it.
Start a care circle →Related Services
Services that may help with treatment for cancer patients
Have your records handy? Upload them for a deeper, personalized analysis →
Related Questions
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
Return ONLY valid JSON. No markdown. Based on 2 medical records: DOCUMENT: IMG_2090.png (Imaging Report) Date:...
```json { "bottomLine": "Your Ga-68 Dotatate PET scans from June and August 2026 show stable metastatic pancreatic neuroendocrine tumor NET with liv
We are in the UK royal marsden. It is kind of hopeless or how to say? Is there any immunetherapy worth to pursue or...
TL;DR: Diffuse midline gliomas DMGs with H3K27M are very challenging, but immunotherapy and targeted approaches are actively being researched—the Roya
It is my daughter she completed 6 weeks of radio and tmz now she is on 3rd cycle of tmz 200mg. We are doing low meth...
TL;DR: Your daughter's treatment plan radiation + TMZ chemotherapy is standard for diffuse midline glioma, and her biomarkers MGMT methylated, EGFR A2
It is h3k27 altered dmg h3k27m negative, egfr a289v myc tp53 mgmt methylated
Your tumor has specific genetic changes H3K27, EGFR, MYC, TP53, MGMT that your doctors will use to guide treatment decisions—these findings help deter